ANALYST Coverage average price for ZYNE $17.83
WHAT PRICE TARGET HAVE ANALYSTS SET FOR ZYNE?
7 brokers have issued 12-month price targets for Zynerba Pharmaceuticals' stock. Their forecasts range from $11.00 to $26.00. On average, they anticipate Zynerba Pharmaceuticals' stock price to reach $17.83 in the next year. This suggests a possible upside of 323.6% from the stock's current price. View Analyst Price Targets for Zynerba Pharmaceuticals.
Canaccord Genuity
Sumant Kulkarni
Cantor Fitzgerald
Charles Duncan, PhD
HC Wainwright & Co.
Oren Livnat, CFA
Jefferies
Biren Amin, PhD
Ladenburg Thalmann & Co.
Michael Higgins
Needham & Company
Serge Belanger
Roth Capital Partners
Jerry Isaacson
--------------------------------------------------------------------------------------------------------------
Zynerba Pharmaceuticals (NASDAQ: ZYNE)
A Rare/Near-Rare Neuropsychiatric Company Autism Spectrum disorders
• Deep pipeline focused on high unmet medical needs; translating into
multi-billion dollar market opportunity with Zygel™(CBD gel)
• Four clinical shots on goal: FXS, DEE, ASD, 22q
• Enrollment complete in pivotal CONNECT-FX FXS trial and in Phase 2
BRIGHT ASD study
• Topline data expected from both trials in 2Q2020
• Experienced team
• Proven development and commercialization track record in transdermal
delivery, orphan diseases, neurology, psychiatry
• Well capitalized
• Cash runway expected into the second half of 2021 - beyond the expected
NDA filing and potential approval in FXS
• Multiple expected near term milestones
$ZYNE
